TL;DR: The core difference in CJC-1295 DAC vs no DAC is the Drug Affinity Complex. DAC covalently binds serum albumin, stretching the half-life to roughly 6–8 days for a sustained GH “bleed.” Mod GRF 1-29 (no-DAC) clears in about 30 minutes, producing sharp pulses that better mimic natural rhythm.
The Core Difference: One Molecule, Two Pharmacokinetic Profiles
Both compounds share the same active core: a synthetic analog of the first 29 amino acids of growth-hormone-releasing hormone (GHRH), with four amino-acid substitutions that resist enzymatic breakdown by dipeptidyl peptidase-IV (DPP-IV). That core is why both are sometimes filed under “CJC-1295.” The divergence is entirely in what is (or is not) attached.
CJC-1295 with DAC carries a maleimido-lysine Drug Affinity Complex (DAC). After subcutaneous injection, this group forms a covalent bond with a free thiol on cysteine-34 of endogenous albumin. Because albumin itself circulates for roughly two to three weeks, the tethered peptide is protected from renal clearance and degradation, so its plasma half-life jumps to approximately 6–8 days in published human data.
CJC-1295 without DAC, more precisely called Modified GRF 1-29 (Mod GRF 1-29), omits that albumin anchor. It is essentially the tetrasubstituted GRF(1-29) core on its own. With nothing binding it to a carrier protein, it is cleared quickly, with a half-life on the order of 30 minutes and a functional window of no more than a few hours.
This single structural choice cascades into every practical difference researchers observe: dosing frequency, the shape of the GH curve, and how the compound is paired in study designs. You can compare the base research profiles for CJC-1295 (no-DAC) and CJC-1295 with DAC side by side to see how the two are catalogued separately.
Values shown in hours on a shared scale; the DAC bar dwarfs the no-DAC form by roughly 300-fold.
Half-Life and the “GH Bleed” vs. Pulsatility Question
Endogenous growth hormone is not secreted at a steady level. It is released in discrete pulses, primarily overnight, governed by the interplay of GHRH, somatostatin, and ghrelin. This pulsatile pattern is thought to matter for how downstream tissues respond, which is central to the DAC-versus-no-DAC discussion.
Because DAC keeps GHRH signalling elevated continuously, it raises the trough (between-pulse) level of GH rather than sharpening individual peaks. Researchers sometimes describe this as a GH “bleed”: a persistent low-level stimulus layered on top of whatever natural pulses occur. A key finding from the human literature is that pulsatility is not abolished by this continuous stimulation — pulses still appear, riding on a raised baseline (Ionescu & Frohman, 2006).
Mod GRF 1-29 behaves in the opposite way. Its brief window of action produces a defined spike of GH release followed by a return toward baseline, more closely echoing a natural pulse. This is why it is frequently studied on a multiple-times-daily schedule timed to specific windows, whereas DAC is studied on a once-weekly-type cadence.
| Attribute | CJC-1295 with DAC | Mod GRF 1-29 (no-DAC) |
|---|---|---|
| Albumin binding | Yes (covalent, via DAC) | No |
| Approx. half-life | ~6–8 days | ~30 minutes |
| GH release pattern | Sustained “bleed,” raised trough | Sharp, defined pulse |
| Pulsatility | Preserved but on elevated baseline | Closely mimics natural pulse |
| Frequency in research protocols | Infrequent (e.g. weekly-type) | Frequent (multiple times daily) |
| Common pairing in study designs | GHRP / ghrelin mimetic | GHRP / ghrelin mimetic (e.g. ipamorelin) |
What the Research Shows
The human evidence base for the DAC form is small but notable for a research peptide. Teichman et al. (2006), published in The Journal of Clinical Endocrinology & Metabolism, ran randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults. A single subcutaneous injection produced dose-dependent increases in mean plasma GH of roughly 2- to 10-fold sustained for six days or more, and IGF-I increases of about 1.5- to 3-fold lasting 9–11 days. The estimated half-life was 5.8–8.1 days, with evidence of a cumulative effect across repeated doses. Importantly, the study reported no meaningful rise in prolactin, cortisol, or ACTH at the doses examined.
A companion paper, Ionescu & Frohman (2006), addressed the pulsatility question directly and concluded that pulsatile GH secretion persists during continuous GHRH stimulation by the DAC analog, while trough and mean GH and IGF-I all rose. That is the strongest human support for the “raised baseline, preserved pulses” model.
Evidence for Mod GRF 1-29 as a specific named compound is thinner and leans on the broader GHRH-analog literature rather than dedicated trials of the exact molecule. The physiology of pairing a GHRH analog with a GH-releasing peptide (GHRP) is better characterized: work such as Alba et al. (2006) in the GHRH-knockout mouse established that a long-acting GHRH analog can normalize growth, and human physiology studies (e.g. Roelfsema et al., 2016; Veldhuis et al., 2008) document strong GHRH-plus-GHRP synergy, where the two acting together can release substantially more GH than either alone. Be honest about the gap: much mechanistic detail for Mod GRF 1-29 is extrapolated from GHRH physiology and animal models, not from large human trials of that named peptide, and neither compound is an approved medicine.
Why the DAC Choice Drives Pairing and Protocol Design
In research settings, GHRH analogs are rarely studied alone because a GHRH signal alone raises GH modestly. The dramatic responses come from combining a GHRH analog with a GHRP/ghrelin mimetic, which suppresses somatostatin and directly triggers release. This synergy is a recurring theme in the physiology literature.
The DAC decision then shapes how that pairing is modelled. With Mod GRF 1-29, its short window is timed to overlap the short window of a GHRP such as ipamorelin, so both stimuli hit the pituitary together and then clear — a clean, pulse-like co-administration. With DAC, the GHRH stimulus is always present, so a co-administered GHRP produces a pulse on top of a continuously elevated GHRH tone. Researchers modelling dose relationships across these scenarios often work through unit conversions and reconstitution maths with a peptide dosing calculator to keep comparisons consistent.
Neither profile is universally “better”; they answer different research questions. Studies interested in sustained IGF-I elevation and convenience of infrequent administration gravitate toward DAC, while those probing the physiological importance of pulse shape favour the short-acting no-DAC form.
Frequently Asked Questions
What is the difference between CJC-1295 DAC and no DAC?
The active GHRH(1-29) core is identical. CJC-1295 with DAC adds a Drug Affinity Complex that covalently binds albumin, extending the half-life to roughly 6–8 days. The no-DAC version, Mod GRF 1-29, lacks that anchor and clears in about 30 minutes, producing short GH pulses instead of sustained elevation.
Does CJC-1295 DAC destroy natural GH pulsatility?
Published human data (Ionescu & Frohman, 2006) suggest it does not abolish pulsatility. Instead, DAC raises the between-pulse trough level of GH, so natural pulses still occur but sit on an elevated baseline. This “raised floor with preserved peaks” pattern is a key finding distinguishing it from a flat, non-pulsatile stimulus.
Why is Mod GRF 1-29 often paired with ipamorelin in research?
GHRH analogs alone raise GH only modestly. Pairing a GHRH analog with a GHRP such as ipamorelin exploits a documented synergy: the GHRP suppresses somatostatin and directly triggers release, so the two together can produce far more GH than either alone. The short half-lives of both align their windows into a single coordinated pulse.
How long does CJC-1295 DAC stay active?
Human trial data (Teichman et al., 2006) estimated a half-life of roughly 5.8–8.1 days. Elevated GH was measurable for six or more days after a single dose, and IGF-I remained raised for 9–11 days. Repeated administration showed a cumulative effect, reflecting the slow turnover of the albumin it is bound to.
Is either version approved for human use?
No. Neither CJC-1295 with DAC nor Mod GRF 1-29 is an approved medicine in the EU or elsewhere. The human data are limited to early-stage research studies. Both are handled strictly as research chemicals for laboratory and educational reference, not for human administration.
References
-
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799–805.
-
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 2006;91(12):4792–4797.
-
Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 2006;291(6):E1290–E1294.
-
Roelfsema F, Yang RJ, Takahashi PY, Erickson D, Bowers CY, Veldhuis JD. Differential effects of estradiol and progesterone on cardiovascular risk factors and GH secretion. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2013;304(11):R925–R933.
-
Veldhuis JD, Keenan DM, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. American Journal of Physiology-Endocrinology and Metabolism, 2008;296(5):E1085–E1092.
-
Vance ML, Kaiser DL, Evans WS, et al. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40): evidence for intermittent somatostatin secretion. The Journal of Clinical Investigation, 1985;75(5):1584–1590.
This article is provided for scientific and educational reference only. All compounds discussed are intended strictly for in-vitro laboratory research use. Nothing here is medical advice, and no statement should be read as a therapeutic claim, an endorsement, or a human dosing recommendation. CJC-1295 (with or without DAC) and Mod GRF 1-29 are not approved for human consumption.